Abstract 1662P
Background
There is a lacuna of studies on adult soft tissue sarcoma (STS) patient’s disease patterns and factors influencing survival outcomes from developing countries in published literature.
Methods
This a single centre prospective observational study conducted at Army Hospital Research & Referral, New Delhi, from Apr 2017 to Mar 2019. One hundred and five consecutive cases of histologically proven Localized STS (excluding Metastatic disease, GIST, Rhabdomyosarcoma, and Ewing’s sarcoma) were included. Baseline demographic and clinical details were noted. Patients were treated with standard protocols after a multidisciplinary tumor board decision. Recurrence-free survival (PFS) and overall survival (OS) were analyzed for the outcome. Statistical analysis was done using SPSS software version 25.
Results
The median age at presentation was 45 years. Extremity (41.8%) was the common primary anatomical site closely followed by retroperitoneum (16%). The most common histopathologic subtype was undifferentiated pleomorphic STS (19%) closely followed by synovial sarcoma (18.1%). Of 105 localized patients, 97 patients underwent surgery, 21 patients received neoadjuvant therapy and reported partial response in 38% (8/21) patients; the remaining 62% (13/21) patients had stable disease. After a median follow up fourteen months, 16 patients had local recurrence, 22 patients had distant metastases, and six patients had died. Two-year RFS and OS rate estimates were 37.3% ± 7.3% and 91.2% ± 3.7%, respectively. On univariate analysis for recurrence-free survival the significant factors were tumor size (>10 cm vs ≤10 cm), HR for recurrence 2.378 (95% CI 1.27 to 4.45, p=0.007), Ki 67 (>20% vs ≤20%), HR for recurrence 2.88 (95% CI 1.52 to 5.44, p=0.001). Age, sex, ECOG PS, histopathological subtype, FNLCC grades, and resection margin status did not significantly predict recurrence. On multivariate analysis, both tumor size and Ki 67 remained statistically significant independent predictors of recurrence-free survival.
Conclusions
Median age is a decade earlier than data from western literature. Tumor size and Ki 67 are the strong independent predictors of recurrence-free survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.